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Search strategy and inclusion criteria: We	 undertook	 a	 scoping	 literature	 review	
using	 a	 systematic	 search,	 including	 academic	 and	 grey	 literature	with	 a	 focus	 on	







parency	 and	accountability.4,5	Methodological	 arguments	 consider	
the	experiential	knowledge	of	patients—acquired	by	their	personal	
experience	of	a	condition—as	valuable	to	improving	the	quality	and	













for	 different	 stakeholder	 groups,	 and	 the	metrics	 of	 interest	will	
therefore	 differ	 accordingly.13	 For	 example,	 for	 researchers	 and	
industry	 partners	 it	 might	 be	 about	 evidence	 that	 patient	 en-
gagement	improves	the	quality	and	efficiency	of	research	and	the	
uptake	of	 findings,	whilst	 for	patients	 it	might	be	more	about	 in-
fluencing	the	R&D	agenda	to	develop	medicines	for	unmet	needs.	
Some	argue	that	evidence	 is	needed	to	 justify	the	 ‘business	case’	
for	engagement.	This	could	also	help	to	establish	a	financial	model	
to	 support	 engagement.2,14,15	 Evaluation	 could	 also	 define	 the	
genuine	 value	 of	 patients’	 contributions,	 contributing	 to	 valued	
rather	 than	 tokenistic	 inclusion	 for	 appearances’	 sake.16	 There	 is	
also	some	resistance;	people	are	concerned	about	assessing	impact	
too	simplistically.	Some	question	whether	it	is	fair	to	evaluate	the	
value	of	patient	 input	 in	 isolation,	and	not	 that	of	others	such	as	
key	scientific	leaders,12	not	least	because	it	may	be	the	synergy	of	
working	 in	partnership	 that	produces	benefit.17	As	mentioned	by	









how	 patient	 engagement	 makes	 a	 difference.3,5,8,12,22-27	 Although	












too,	 particularly	 in	 an	 area	of	 science	where	direct	 comparison	 to	
evaluation	 approaches	 or	 outcomes	 associated	with	 patient	 engagement.	No	 date	
limits	were	applied	other	than	a	cut-off	of	publications	after	July	2018.
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This	 work	 is	 part	 of	 the	 PARADIGM	 project,	 a	 public-private	
partnership	that	 is	developing	ways	to	ensure	that	patients	are	al-
ways	meaningfully	 involved	 in	 the	development	of	medicines.	The	
impact	of	patient	engagement	may	differ	at	different	points	 in	the	
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We	 undertook	 a	 scoping	 review	 of	 published	 academic	 and	 grey	
literature	 as	 recommended	 by	 Arksey	 and	O’Malley,	 also	 drawing	









ensure	capture	of	 related	publications	 in	other	areas	of	health	 re-
search.	One	of	the	challenges	was	the	variety	of	terminology.	For	ex-
ample,	the	words	“measure,”	“metric”	and	“indicator”	are	often	used	
















the	 clarification	 of	 concepts	 and	 search	 terms	when	 interrogating	
large,	diverse	fields	of	literature.48
Accordingly,	 with	 the	 assistance	 of	 a	 specialist	 librarian,	 we	
searched	CINAHL,	Embase,	Medline,	PsychINFO	and	PubMed	da-
tabases	for	peer-reviewed	published	literature.	The	following	key	





ommended	 by	 consortium	 partners	 and	 external	 stakeholders	
were	added	manually,	and	reference	 lists	of	 items	 included	were	
searched	for	additional	publications.	All	searches	were	conducted	
between	1	May	2018	and	31	 July	2018.	The	 search	was	 limited	
to	publications	 in	English.	We	excluded	articles	that	did	not	pro-
vide	 information	on	possible	evaluation	approaches	or	outcomes	
associated	 with	 patient	 or	 public	 engagement.	 No	 date	 limits	
were	 applied	 other	 than	 a	 cut-off	 of	 publications	 after	 31	 July	
2018.	Following	completion	of	the	search,	duplicated	items	were	
removed.
2.2 | Study selection and data extraction
Two	researchers	(TF,	LV)	independently	screened	all	items’	title	and	
abstract.	To	ensure	inter-rater	reliability,	items	were	marked	for	in-
clusion	 or	 exclusion	 with	 each	 researcher's	 initials,	 discrepancies	










information	 from	 each	 item,	 including	 the	 publication	 year	 and	
focus,	country	of	origin,	methodology,	patients	 involved	as	part-
ners,	use	of	a	framework	or	model,	definitions	included,	outcome	
and/or	 impact	 on	 research,	 benefits	 and	 costs	 per	 stakeholder	
group,	measurement	or	evaluation	methods	suggested	or	applied.	
TA B L E  2  Search	terms























Public	involvement Agenda	setting  
User	involvement   
Client	involvement   
Consumer	involvement   
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When	available,	context	and	process	criteria	were	also	 included.	
Both	researchers	extracted	data	 independently	from	30%	of	the	
scientific	 articles	 and	 then	 compared	 their	 findings	 to	 agree	 the	
















decision-making	 point	 focus	 of	 articles	was	 interpreted	 by	 the	 re-
searchers	if	not	defined	in	the	article.	Benefits	and	costs	that	could	






during	 a	PARADIGM	meeting	held	 in	 London,	18	 July	2018.	This	
session	provided	valuable	input	on	how	best	to	present	and	catego-
rize	 the	 results.	 Participants	 in	 the	meeting	 included	 representa-
tives	 from	 patient	 organizations,	 pharmaceutical	 companies	 and	















in	 the	 United	 Kingdom	 in	 an	 academic	 setting.	We	 found	 largely	
qualitative	studies	and	literature	reviews.	Sixteen	studies	reported	
F I G U R E  1  Article	selection	PRISMA	flow	diagram
Records from databases aer 
duplicates removed 
(n = 1305)
Records from grey literature and hand 
searching aer duplicates removed 
(n = 47)
Records included for full text reading 
(n = 168)
Records excluded aer full text reading:
• No informa on on possible evalua on 
approaches or outcomes
• No methods for evalua ng outcomes 
and impacts of pa ent engagement 
prac ces in health research or health 
technology assessment 




Included Items included for data extrac on 
(n = 91)
Records included for Ti/Ab screening 
(n = 1352)
Records excluded aer screening Ti/Ab:
• Not wrien in English 
• Not about evalua on of pa ent 
engagement
(n = 1184)




sidering	 the	 three	 decision-making	 points,	 which	 were	 relevant	











into	11	domains	 and	mapped	with	28	possible	 indicators	 for	 their	
evaluation.	Tables	4	 and	5	provides	 an	overview	of	 indicators	per	
domain.	Please	refer	to	Appendices	S3–S5	for	more	detailed	indica-
tors,	evaluation	methods	and	tools.
3.1.1 | Benefits of patient engagement in research 
priority setting
Literature	 suggests	 that	 patient	 engagement	 in	 research	 priority	
setting	 has	 several	 benefits.	 We	 identified	 four	 unique	 benefits	
and	nine	possible	 indicators.	We	clustered	 the	benefits	 into	 three	
domains:	usability	benefits,	societal	benefits	and	funding	benefits.	




interventions	or	 technologies.30	Societal	benefits	 refer	 to	 the	way	
public	and	private	resources	are	allocated,	for	example	more	appro-
priate	resource	allocation	based	on	patients’	needs.30	Funding	ben-
efits	 refer	 to	new	 funding	and	 funding	opportunities,	 for	example	
success	 in	gaining	 funding	due	to	enhanced	credibility	of	 research	
proposals.25,29-32,56-58
In	the	 literature,	quantitative	methods	are	used	to	collect	 infor-
mation	about	 the	perceived	 importance	of	 studies	by	patients,	 the	
perceived	influence	of	stakeholders	in	research	priority	setting,23,59 
or	 to	 compare	 academic	 and	 lay	 scores	 assigned	 to	 research	 pro-
posal	 evaluation.60	 For	 example,	 studies	 suggest	 rating	 the	 impor-
tance	or	influence	of	partners	in	developing	the	research	topics.23,59 
Qualitative	methods	are	used	 to	explore	 the	 relevance	of	 research	
topics	and	how	patients’	experiential	knowledge	helped	shape	the	re-
search	question.30	The	Patient-Centered	Outcome	Institute	(PCORI)	
uses	mixed	methods	 (survey,	 focus	groups,	database	review)	 to	ex-
plore	the	perceptions	 incorporated	 into	the	topic	selection	process	








expert-led	 research	 priorities	 in	 diabetes.62	 Additionally,	 documen-
tary	analyses	(eg	review	of	minutes,	grant	applications,	reports)	may	
be	 conducted	 to	 compare	 patient	 input	 and	 responsiveness	 to	 pa-
tients’	ideas.54,61,63
3.1.2 | Benefits of patient engagement in the 
design of clinical trials
We	 identified	 ten	 unique	 benefits	 of	 patient	 engagement	 for	 the	
design	 of	 clinical	 trials,	 including	 13	 possible	 indicators.	We	 clus-
tered	 the	 benefits	 into	 three	 domains:	 ethical	 benefits,	 meth-
odological	 benefits	 and	 study	 quality	 benefits.	 Several	 studies	
described	 ethical	 benefits	 such	 as	 a	 more	 appropriate,	 inclu-
sive	 and	 sensitive	 research	 design.8,17,29,30,52,55,58	 Furthermore,	
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studies	 described	 methodological	 benefits	 such	 as	 more	 appro-
priate	 wording	 and	 timing	 of	 research	 instruments	 and	 interven-
tions,17,20,22,24,25,27,29,31,55,56,64-68	 and	 improved	 consent	 forms	 and	
accessible	recruitment	materials.4,20,24,25,29,31,40,55,56,67,68	Study	qual-
ity	 benefits	 are	 also	 reported,	 for	 example	 improved	 trial	 recruit-
ment	and	retention.23,24,29,40,69
TA B L E  4  Summary	of	benefits	for	research	and	development	mapped	with	reported	indicators	for	evaluation
Research priority setting
























Design of clinical trials

























Regulatory and HTA processes












Developmental benefits (9) Examples of indicators related to developmental benefits
Knowledge	and	public	awareness	of	products72 None	reported
Democratic	accountability	and	transparency72  
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The	 literature	 suggests	 several	 indicators	 and	 methods	 for	
the	 evaluation	 of	 patient	 engagement	 in	 the	 design	 of	 clinical	
trials.	For	example,	Guarino	et	al	measured	participants’	under-
standing	of	the	study	consent	form,	using	the	Informed	Consent	
Questionnaire-4	 questionnaire.	 The	 reading	 levels	 of	 the	 con-
sent	 forms	 were	 assessed	 using	 Flesch-Kincaid	 reading	 level	
scores.70	Rating	the	impact	of	patient	engagement	on	study	vol-
unteer	 attitudes	 about	 aspects	 of	 the	 participation	 process	 (eg	
ease	of	understanding	the	 informed	consent	form;	convenience	
of	study	visits	and	procedures)	 is	also	suggested.59	Other	stud-
ies	 suggest	 collecting	 data	 on	 the	 number	 of	 studies	 that	 gain	
research	 ethics	 committee	 approval,12	 the	 number	 of	 protocol	
amendments59	 and	 the	 number	 and	 type	 of	 patient-reported	
outcomes.61	 Furthermore,	 several	 studies	 have	 assessed	 study	
quality	 benefits,	 for	 example	 recruitment	 rates,	 using	 differ-
ent	 quantitative	 methods.40,69,70	 Iliffe,	 McGrath	 and	Mitchell40 
compared	 recruitment	 levels	 before	 and	 after	 the	 involvement	
of	the	public.	Guarino	et	al70	also	conducted	a	comparison;	they	
assessed	 the	effect	of	 two	different	 consent	documents	on	 re-
cruitment	 levels	 using	 one	 consent	 form	 developed	 by	 a	 con-
sumer	 focus	 group	 compared	 with	 another	 developed	 by	 the	













suggested	 for	 gathering	 information	 about	participants’	 experi-
ences	of	taking	part	in	a	clinical	trial.15
3.1.3 | Benefits of patient engagement in regulatory 




study	 uptake	 benefits	 and	 developmental	 benefits.	 Instrumental	
benefits	 are	 related	 to	 improving	 the	 relevance	 of	 assessment	 to	








Literature	 suggests	 a	 few	 methods	 to	 evaluate	 the	 bene-
fits	 of	 patient	 engagement	 in	 regulatory	 processes	 and	 HTA.	
Quantitative	methods	are	suggested	to	assess	study	uptake	ben-
efits	 such	 as	 the	 time	 to	 response/approval	 of	 regulators	 and	 a	
change	 in	 the	proportion	of	 drugs	 recommended	 for	 reimburse-
ment.3,74	Furthermore,	quantitative	methods	could	be	used	to	as-
sess	the	perceived	impact.	For	example,	the	European	Medicines	
Agency	 has	 used	 a	 survey	 to	 assess	 the	 perceived	 added	 value	
of	 patient	 input	 in	 scientific	 advice	 processes	 and	 feedback.75 
Qualitative	 methods	 can	 also	 be	 used	 to	 explore	 measures	 of	
change	or	uptake	of	patients’	 input.	For	example,	Abelson	et	al76 
assessed	how	patients’	 input	 informed	the	HTA	process	 through	
document	analysis,	 interviews	and	observations.	Dipankui	et	al77 
used	semi-structured	 interviews	and	document	analysis	 (eg	HTA	
reports,	 minutes)	 to	 evaluate	 how	 patient	 engagement	 changed	
the	HTA	report	and	its	recommendations.
3.2 | Costs and challenges of patient engagement in 
research and development
Limited	 studies	 have	 published	 costs	 and	 challenges.	 Of	 those	





and	providing	 training	 and	 education	 for	 users	 and	 researchers,	
and	 the	 additional	 time	 needed	 for	 users	 to	 read	 and	 comment	
on	 documentation.20	 Only	 two	 studies	 suggest	 that	 patient	 en-
gagement	 could	 potentially	 result	 in	 a	 more	 homogenous	 sam-





engagement	 led	 to	 scientific	 and	ethical	 conflict	 in	protocol	de-
sign.	Also,	patient	engagement	may	lead	to	tokenistic	engagement	
TA B L E  5  Summary	of	costs	for	research	and	development	
mapped	with	reported	indicators	for	evaluation
Various decision‐making points
Non‐financial costs (10) Examples of indicators related to 











Financial costs (11) Examples of indicators related to 
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and	can	lead	to	power	struggles	between	researchers	and	patient	
partners.20	Furthermore,	stakeholders	have	raised	concerns	that	
engaged	 patients	 may	 want	 to	 see	 their	 clinical	 trials	 succeed,	
and	 as	 a	 result,	 these	 patients	may	 bias	 the	 study	 findings.59	 It	
was	also	reported	that	a	number	of	clinical	research	professionals	
fear	that	patient	centricity	is	pushing	them	to	discard	traditional	






TA B L E  6  Summary	of	benefits,	costs	and	challenges	per	stakeholder	group
Individuals and 


























































































supporting	 patients,	 financial	 payment/rewards,	 total	 costs	 of	 ex-
penses	 reimbursed	 to	 all	 patients	 for	 their	 involvement	 and	other	
costs	(including	parking	permits,	room	booking,	audio-visual,	equip-
ment).	 A	 separate	 questionnaire	 developed	 for	 patients	 includes	




used	 to	gather	 insights	 into	 time	and	costs.27	Open	questions	 are	
used	to	gather	insights	into	(non-financial)	negative	impacts.24
3.3 | Benefits, costs and challenges for stakeholders
Studies	 that	 assessed	 patient	 engagement	 for	 individuals	 and	 or-









and	S2	 for	more	detailed	 information	on	benefits,	 costs	 and	chal-
lenges	for	patients	and	other	stakeholders.
Multiple	 tools	have	been	developed	 to	assess	 the	benefits	and	
costs	for	stakeholders.	The	Evaluation	Toolkit	is	a	resource	designed	
for	practitioners	of	the	health	sector,	produced	after	the	completion	























4.1 | Reflection on our findings
A	total	of	18	benefits	and	five	costs	of	patient	engagement	at	the	
three	decision-making	points	were	 identified	 in	 this	 review.	These	
were	grouped	into	11	domains	and	mapped	with	28	possible	indica-
tors	for	their	evaluation.	Little	is	known	about	the	validity	and	per-
formance	of	 these	 indicators	 as	most	were	 suggested	 rather	 than	
applied,	or	used	in	single	studies.	Those	studies	mostly	considered	
a	single	indicator	(eg	recruitment	rate)	for	trying	to	answer	a	single	































comparison	 across	different	 projects.16	 To	build	 an	 evidence	base,	
conceptual	and	practical	guidance	and	some	 level	of	consensus	on	
measurable	 impacts	 are	 needed.	 This	 has	 also	 been	 suggested	 by	
other	 authors.13,30	 However,	 whilst	 a	 standardized	 approach	 may	
be	appealing	to	health	research	and	development	communities,	it	is	
problematic	 in	 the	 complex	 and	 contextually	 dependent	 arenas	 of	
patient	engagement.81	 It	might	 inhibit	capacity-building	 in	projects	
and	makes	changes	difficult;	arguably,	 this	undermines	the	original	
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rationale	 for	 patient	 engagement.	 The	 tension	 between	 obtaining	
comparable	data	on	patient	engagement	by	using	metrics	(standard-
ized	 or	 agreed	 techniques	 for	 gathering	 information)	 and	 tailored	




4.2 | Strengths and limitations of this review









sidered	 patient	 engagement	 in	 the	 HTA	 process,	 and	 only,	 three	
publications	were	authored	by	(and	for)	the	pharmaceutical	indus-
try.	 Furthermore,	 of	 the	 papers	 included	 in	 our	 review,	 very	 few	
reported	that	they	had	involved	patients;	therefore,	the	conclusions	
derived	from	the	studies	may	be	based	on	the	perspectives	of	re-














or	 the	 indicators	 per	 stakeholder	 group.	 Furthermore,	we	 cannot	
draw	hard	conclusions	about	the	relationship	between	 input,	out-
comes	and	 impact	with	 respect	 to	 the	benefits	 and	 costs	 for	 the	
people	and	organizations	 involved	 in	patient	engagement.	Finally,	
we	had	to	exclude	articles	not	published	in	English.	Whilst	we	are	




For	 patient	 engagement	 in	 the	 development	 of	 medicines	 to	
become	 standard	 practice	 at	 the	 key	 decision-making	 points	
of	priority	 setting,	 clinical	 trial	 design	and	 regulatory	 and	HTA	
processes,	 benefits	 need	 to	 be	 demonstrable	 to	 all	 stakehold-
ers.	This	literature	review	has	mapped	benefits,	costs	and	chal-
lenges	with	 indicators	 in	 current	 literature.	Discrete	 tools	 and	
methods	for	evaluation	are	less	apparent,	as	is	evidence	of	their	
application.	The	approaches	to	evaluation	we	found	are	largely	
qualitative,	 and	 our	 review	 suggests	 that	 there	 are	 few	 quan-








more	 consideration	 (rather	 than	 the	 current	 focus	 on	 benefits	 for	
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